Navigation Links
Micromet Closes $40 Million Private Equity Placement
Date:10/3/2008

registration requirements. Micromet, Inc. has agreed to file a registration statement with respect to the shares on or before November 3, 2008. This news release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... 10, 2014   Ceres, Inc . (Nasdaq: ... announced today financial results for the three months ended ... business. Ceres reported that the company and ... this growing season in Brazil, which concluded in June, ... sorghum evaluation areas for part of the growing season. ...
(Date:7/10/2014)... been extremely challenging because there are many genetic variants ... disease. Now investigators reporting in the July 3rd issue ... describe a strategy that may help reveal how ... or environmental exposures to affect the development of the ... may predispose individuals to schizophrenia. , The work ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2
... ... ... conservation, better materials for frontier technologies and new economic engines, and breakthroughs in understanding diseases: ... enabled by an upgrade to the Advanced Photon Source (APS) at the U.S. Department of ...
... BANGALORE, India , May 3 The Global ... today at the 2010 BIO International Convention that they have ... development and clinical use of drugs against tuberculosis (TB), including ... with TB are resistant to at least one of today,s ...
... , May 3 The American College ... American Gastroenterological Association (AGA)Institute today announced an innovative initiative ... at Digestive Disease Week ® 2010.  The peer-driven campaign ... lines of the diagnosis and treatment of hereditary angioedema ...
Cached Biology Technology:Upgrade to Advanced Photon Source Announced by DOE 2Upgrade to Advanced Photon Source Announced by DOE 3Upgrade to Advanced Photon Source Announced by DOE 4TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 2TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 4ACAAI and AGA Partner to Raise Awareness of Hereditary Angioedema Through 'HAE: Learn About It, Talk About It' 2ACAAI and AGA Partner to Raise Awareness of Hereditary Angioedema Through 'HAE: Learn About It, Talk About It' 3ACAAI and AGA Partner to Raise Awareness of Hereditary Angioedema Through 'HAE: Learn About It, Talk About It' 4ACAAI and AGA Partner to Raise Awareness of Hereditary Angioedema Through 'HAE: Learn About It, Talk About It' 5
(Date:7/11/2014)... Bone and Mineral Research awarded Michael F. Holick, PhD, ... the 2014 Louis V. Avioli Award. Holick, a professor ... known for revolutionizing the understanding of vitamin D and ... honors a member of the American Society for Bone ... and mineral basic research. It is named for ASBMR,s ...
(Date:7/11/2014)... set a "mouse TRAP" to capture the early signs ... published in the Journal of Clinical Investigation . ... TRAP to extract cellular and genetic information from a ... the Rockefeller Institute for Medical Research in 2008, TRAP ... or ribosomes, of the cell type of interest. Scientists ...
(Date:7/11/2014)... China Researchers from Salk Institute for Biological Studies, ... evaluated the safety and reliability of the existing ... new method, TALEN-HDAdV, which could significantly increased gene-correction ... This study published online in Cell Stell ... stem cell-based gene therapy. , The combination of ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... 2012) Researchers have gained new insight into why ... achieving a folate concentration considered optimal for reducing the risk ... absence of folate deficiency in the general Canadian population. ... main reason why some women are not achieving levels optimal ...
... Diego, CA, April 10, 2012 The neighborhoods in which ... role in whether or not they eat a healthy diet, ... studies in a special theme issue of the American ... six studies uses the latest concepts and methods in geographic ...
... Boston, MA Meningioma, the most common primary brain ... percent of all primary brain tumors. The most consistently ... ionizing radiation. In the largest study of its ... University School of Medicine, Duke University, UCSF and Baylor ...
Cached Biology News:Geographic information systems demonstrate links between health and location 2Dental X-rays linked to common brain tumor 2
... MEGAscript RNAi Kit is optimized ... mass amounts of ready-to-use dsRNA ... systems. The MEGAscript RNAi Kit ... high-yield transcription technol-ogy and includes ...
... actuators as building blocks, Parker can ... ,robotic solutions that are ideal for ... base ,system, Parker can also integrate ... structures, and ,guarding., Standard or ...
... is the smallest electronic pressure controller available ... Parker configured this unit specifically for the ... Used in carrier gas flow control, microfluidic ... and hydro-dynamic focusing, the OEM-EPC offers external ...
...
Biology Products: